SOPHiA GENETICS' Board of Directors Elects Troy Cox as New Chairman

Lausanne, Switzerland and Boston (ots/PRNewswire) - SOPHiA GENETICS, leader in
Data-Driven Medicine, announced today that former Foundation Medicine CEO Troy
Cox has been elected as Chairman of the Board of Directors, effective March 1,
2020. He is replacing Antoine Duchateau, who has served as chairman since 2013
and will continue as a board member. Cox joined the company in July of 2019 as a
member of the board.

"This announcement signals how much of an asset Troy has been for SOPHiA
GENETICS in this short amount of time," said Jurgi Camblong, CEO and Co-founder.
"I am delighted that he will assume the chairmanship of the company's board, as
his impressive expertise will help us to further expand our community of
partners and the scope of new clinical-grade applications to further the success
of our mission. I am deeply grateful to Antoine Duchateau for his outstanding
guidance over the past 6 years as Chairman of the Board of Directors. His
experience has been extremely valuable in driving SOPHiA GENETICS to its current
position."

Recent technological advances help SOPHiA GENETICS leverage even more
multi-modal data, ultimately leading SOPHiA into a new era in healthcare. Fast
and accurate diagnostics, personalized treatment options, longitudinal patient
monitoring and drug development optimization are the concrete benefits of
Data-Driven Medicine. This idea has shaped Troy Cox's entire career, and his
election as Chairman of the Board is a direct testimony thereof.

A healthcare industry visionary leader, Troy Cox formerly served as CEO of
Foundation Medicine (FMI), where his work was recognized by the acquisition of
the company by Roche in 2018. Prior to FMI, he led US BioOncology for a period
of unprecedented growth as Senior Vice President and Officer at Genentech,
participating in the launch of nearly half of the products. Earlier on, Mr. Cox
held executive and senior positions at numerous healthcare companies including
UCB BioPharmaceuticals, Sanofi-Aventis, and Schering-Plough.

"I'm proud to take a leadership role at this important time of expansion and to
be part of SOPHiA GENETICS mission. Thanks to its global and universal approach
that already benefits more than 1,000 hospital partners, SOPHiA is uniquely
positioned to lead and promote an important movement in the entire ecosystem"
said Troy Cox. "Together, we democratize Data-Driven Medicine, enabling clinical
experts to access the full potential of new-generation health data and
positively impact patients' lives all around the world."

About SOPHiA GENETICS

SOPHiA GENETICS is a health tech company democratizing Data-Driven Medicine to
improve health outcomes and economics worldwide. By unlocking the power of
new-generation health data for cancer and rare diseases management, the
universal SOPHiA Platform allows clinical researchers to act with precision and
confidence. The company's innovative approach enables an ever-expanding
community of over 1'000 institutions to benefit from knowledge sharing,
fostering a new era in healthcare. SOPHiA's achievement is recognized by the MIT
Technology Review's "50 Smartest Companies".

More info: SOPHiAGENETICS.COM (https://sophiagenetics.com/), follow
@SOPHiAGENETICS (https://twitter.com/SOPHiAGENETICS) on Twitter.

Photo - https://mma.prnewswire.com/media/1093091/SOPHiA_Troy_Cox.jpg

Media contacts

BAM Communications for SOPHiA GENETICS

sophiagenetics@bamcommunications.biz

Global Media Contact

Sophie Reymond
Media Relations Specialist
sreymond@sophiagenetics.com
Tel: +41-021-694-10-75

USA Media Contact

Don Granese
Media Relations Manager
dgranese@sophiagenetics.com
Tel: +1-857-263-7972

Additional content: https://www.presseportal.de/pm/114431/4525849
OTS: Sophia Genetics

Original-Content von: Sophia Genetics, übermittelt durch news aktuell